Frontiers in Cardiovascular Medicine (May 2023)

The role and implications of left atrial fibrosis in surgical mitral valve repair as assessed by CMR: the ALIVE study design and rationale

  • Sulayman el Mathari,
  • Jolanda Kluin,
  • Jolanda Kluin,
  • Luuk H. G. A. Hopman,
  • Pranav Bhagirath,
  • Maurice A. P. Oudeman,
  • Alexander B. A. Vonk,
  • Aart J. Nederveen,
  • Susanne Eberl,
  • Robert J. M. Klautz,
  • Robert J. M. Klautz,
  • Steven A. J. Chamuleau,
  • Pim van Ooij,
  • Marco J. W. Götte,
  • Marco J. W. Götte

DOI
https://doi.org/10.3389/fcvm.2023.1166703
Journal volume & issue
Vol. 10

Abstract

Read online

BackgroundPatients with mitral regurgitation (MR) commonly suffer from left atrial (LA) remodeling. LA fibrosis is considered to be a key player in the LA remodeling process, as observed in atrial fibrillation (AF) patients. Literature on the presence and extent of LA fibrosis in MR patients however, is scarce and its clinical implications remain unknown. Therefore, the ALIVE trial was designed to investigate the presence of LA remodeling including LA fibrosis in MR patients prior to and after mitral valve repair (MVR) surgery.MethodsThe ALIVE trial is a single center, prospective pilot study investigating LA fibrosis in patients suffering from MR in the absence of AF (identifier NCT05345730). In total, 20 participants will undergo a CMR scan including 3D late gadolinium enhancement (LGE) imaging 2 week prior to MVR surgery and at 3 months follow-up. The primary objective of the ALIVE trial is to assess the extent and geometric distribution of LA fibrosis in MR patients and to determine effects of MVR surgery on reversed atrial remodelling.ImplicationsThis study will provide novel insights into the pathophysiological mechanism of fibrotic and volumetric atrial (reversed) remodeling in MR patients undergoing MVR surgery. Our results may contribute to improved clinical decision making and patient-specific treatment strategies in patients suffering from MR.

Keywords